Specialized pharmaceutical manufacturer Jeronselvain announced on the 25th that it held the ‘PDRN KOL Meeting’ at the Koreana Hotel in Seoul, targeting key medical professionals both domestically and internationally.
Jeronselvain invited major domestic and overseas Key Opinion Leaders (KOLs) to share the latest medical trends and prescription cases centered on the prescription drug 'Selvain Injection,' a polynucleotide (PDRN)-based treatment for pain and inflammation.
According to the company, attendees focused on the medical competitiveness of ‘Selvain Injection’ and engaged in in-depth discussions on efficacy and safety data, demonstrating high concentration and increasing trust.
Kim Deok-gyu, CEO of Jeronselvain, stated, “Our ‘Selvain Injection’ utilizes patented Prism Technology (Prism-T) to deliver a unique drug with a consistent low molecular size, and we are concretizing our overseas expansion strategy.” He added, “Next year, we will hold the world’s first PDRN-only symposium to build consensus around ‘Selvain Injection.’”
The meeting featured speakers including Yoon Jong-il, director of Yeon Dental Clinic; Jang Byung-chul, professor at Keimyung University; and Cho Nam-jun, professor at Nanyang Technological University in Singapore. They explained the tissue regeneration effects of ‘Selvain Injection’ and participated in networking sessions to share knowledge and information for advancing into the global market, fostering mutual cooperation and communication.
Yoon Jong-il, director of Yeon Dental Clinic, emphasized, “According to the Ministry of Food and Drug Safety’s database, PDRN has shown no serious or unexpected adverse events. It is highly effective in treatments where immune balance is disrupted and difficult to recover, and in dentistry, PDRN regenerative injection therapy significantly accelerates inflammation recovery.”
Jang Byung-chul, professor at Keimyung University, explained, “Jeronselvain’s ‘Selvain Injection’ employs patented technology with optimized extraction methods and manufacturing facilities, resulting in different efficacies, indications, and mechanisms of action.” He added, “It has also been proven highly effective in healing wounds in human gingival fibroblasts.”
Cho Nam-jun, professor at Nanyang Technological University, Singapore, stated, “We anticipate that Jeronselvain’s ‘Selvain Injection’ can be utilized in lipid nanoparticle (LNP) formulation technology to develop various products.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
